Resources

Client Alerts, News Articles, Blog Posts, & Multimedia

Everything you need to know about BMD and the industry.

Ohio Med Spas: Peptide Do's and Do Not's

Client Alert

Recent Ohio Board of Pharmacy (“BOP”) guidance has highlighted compliance considerations surrounding the use of peptides in med spas.  Owners and operators of med spas will want to keep these considerations in mind as the use of peptides, especially GLP-1 medications, expands.  

Certain peptide drugs are FDA approved medications and can be used in med spas. However, not every peptide-based drug is created equal or is approval by the FDA. According to BOP guidance, some peptides, such as Retatrutide, are not currently FDA approved.[1] In addition, many peptide-based drugs, such as Semaglutide or BPC-157 peptides, cannot currently be compounded.[2]

The BOP conducts regular inspections of med spas and has revoked or suspended several med-spa’s TDDD licenses for violations surrounding the use of peptides. The most common violations are purchasing medication from an unlicensed seller, purchasing and utilizing medication marked “for research purposes only,” purchasing non-FDA approved medication, and obtaining foreign sourced medication.   

When determining which peptides your med-spa can utilize, it is important to keep the following considerations in mind:

  • Only use peptides that are FDA approved.
  • Do not purchase peptides from unlicensed sellers.
  • Do not use peptides labeled “for research purposes only.”
  • Ensure compliance with compounding requirements, including not making prohibited copies of peptides.
  • Properly store any peptides prior to their use.

If you have questions regarding BOP compliance or how using peptides may impact your practice, please contact BMD Member Jeana Singleton at jmsingleton@bmdllc.com or 330-253-2001.     


[1] Compounding of Glucagon-like Peptide-1 Drug Products (GLP-1) in Ohio, Ohio Board of Pharmacy, last accessed April 23, 2026.

[1] Ten Common Prescriber Clinic and Medical Spa Violations, Ohio Board of Pharmacy, last accessed April 23, 2026. See also, Compounding of Glucagon-like Peptide-1 Drug Products (GLP-1) in Ohio, Ohio Board of Pharmacy, last accessed April 23, 2026.


RNs and APRNs Take Note: Ohio Board of Nursing Mandates a New CE Reporting Period

Ohio’s Board of Nursing has updated the continuing education reporting period for RNs and APRNs. Beginning March 26, 2026, CE credits must be completed between July 1 and June 30 of odd-numbered years, replacing the previous November to October timeframe.

Substance Use Disorder Providers: 42 CFR Part 2 Now Enforceable

Updates to 42 CFR Part 2 are now enforceable, bringing significant changes to how substance use disorder (SUD) records are handled. The Final Rule aligns Part 2 more closely with HIPAA, introduces updated penalties, allows a single patient consent for treatment, payment, and operations, and adds new requirements for Notices of Privacy Practices. It also creates a formal definition of SUD counseling notes and imposes strict consent requirements for their use and disclosure. Providers should review and update policies to ensure compliance.

AAA Introduces AI-Assisted Arbitrator for Certain Disputes

The American Arbitration Association has introduced an AI-assisted arbitration platform designed to streamline certain document-based disputes. While a human arbitrator still makes the final decision, the technology can improve efficiency, reduce costs, and accelerate case resolution. Companies should weigh these benefits against considerations such as transparency, risk, and contractual requirements before adopting AI-assisted arbitration.

Quiet Hours Texts and TCPA Claims: Consent Remains King as Courts Divide on Text Messages

Businesses face increasing TCPA lawsuits over off-hours marketing texts, but recent court decisions highlight strong defenses. Clear consumer consent and updated terms and conditions can defeat many claims, while a growing number of courts are finding that text messages are not “telephone calls” under the statute. Proactive compliance measures, including clickwrap agreements and forum-selection clauses, are critical to reducing risk.

New Ohio Reporting Requirements for Non-Residential Contractors

Ohio’s E-Verify Workforce Integrity Act, effective March 19, 2026, requires all nonresidential construction companies, subcontractors, and labor brokers to use E-Verify to confirm employee work eligibility on projects across the state. The law applies regardless of company size and carries financial penalties and potential restrictions on future state contracts for noncompliance. Some uncertainty remains around requirements for existing employees, making early compliance planning important.